Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis

J Am Coll Cardiol. 2026 Feb 10;87(5):502-504. doi: 10.1016/j.jacc.2025.10.019. Epub 2025 Dec 3.

¹ Department of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Department of Medicine, Division of Cardiology, Emory University, Atlanta, Georgia, USA.
³ Department of Medicine, Section of Cardiovascular Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA; Amyloidosis Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
⁴ Department of Medicine, Section of Cardiovascular Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA; Amyloidosis Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA. Electronic address: omar.siddiqi@bmc.org.

No abstract available

Keywords: acoramidis; tafamidis; transthyretin amyloid cardiomyopathy; vutrisiran.

Publication types